Skip to content

Cryoneurolysis in Patients Awaiting Total Hip and Knee Arthroplasty

Cryoneurolysis as an Interim Pain Control Strategy in Patients Awaiting Total Hip and Knee Arthroplasty: a Prospective Observational Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06942078
Enrollment
30
Registered
2025-04-24
Start date
2026-06-01
Completion date
2028-12-31
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Arthropathy, Knee Arthropathy

Brief summary

During the COVID-19 pandemic, there was a drastic increase in surgical wait times across Canada, notably for patients awaiting total knee and hip arthroplasty. Currently the average wait time for total hip arthroplasty (THA) in Alberta is 16 weeks with the 90th percentile of wait times being 47 weeks. The average wait for total knee arthroplasty (TKA) in Alberta is 20 weeks with the 90th percentile of wait times being 60 weeks. As the waitlist for these surgeries grows and with limited resources to increase the number of surgeries being performed, there is a critical need for strategies to manage the pain experienced by patients during these long waiting periods. Many patients awaiting surgery are placed onto long-term opioid therapy to manage their pain. There are, however, significant risks associated with the extended use of opioids for pain management, such as addiction, opioid abuse, increased risk of overdose, increased risk of fractures, and increased risk of adverse cardiac events. Recognizing these risks, different strategies need to be employed to attempt to minimize the opioid burden faced by those waiting for surgery. One potential strategy is to utilize regional anesthesia for analgesia rather than relying on opioids. Regional anesthesia with nerve blocks using local anesthetic has been used in the management of preoperative pain for patients awaiting surgery for hip fracture and has been shown to be effective in reducing pain, opioid use, and the risk of serious adverse effects. However, for patients with hip fractures, their surgery usually occurs within 36 hours due to significant risks which occur beyond that timeframe. For patients waiting for THA and TKA, the surgical wait time could be weeks to months. Providing daily nerve blocks or even weekly catheters for an individual waiting up to a year for surgery is not sustainable and carries significant risks with repeated injections. New regional anesthesia techniques lasting a longer period of time are needed. One promising intervention is to utilize cryoneurolysis. Cryoneurolysis involves treating targeted nerves using extremely low temperatures. This disrupts nerve conduction and pain impulses. Importantly, connective tissue components of the nerve are left intact allowing for regeneration over time. Because of this, cryoneurolysis is a well-established treatment for chronic and acute pain due to its effectiveness and low risk safety profile. While cryoneurolysis is well-established in its use treating chronic and surgical pain, one limitation is that it is focused primarily on postoperative pain. Our study intends to primarily evaluate the efficacy of cryoneurolysis as a preoperative pain management intervention. Establishing the use of cryoneurolysis for preoperative pain will provide a valuable resource for reducing the pain patients experience while awaiting surgery, leading to decreased opioid use and improved overall well-being. The investigators will be recruiting 30 participants total (15 having TKA and 15 having THA) that will be given cryoneurolysis while waiting for their surgery.

Interventions

PROCEDURECryoneurolysis

Targeting of specific nerves related to surgical procedure using very low temperatures

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Currently awaiting THA or TKA (have signed consent for surgery) * Osteoarthritis as a primary diagnosis for THA or TKA * Currently taking regular daily opioids for at least one month * No allergies to local aesthetics * Speaks and understands English * Over 18 years old * Lives within a 1-hour distance of the hospital where the study is taking place or willing to travel to the hospital for the interventions and follow up.

Exclusion criteria

* If surgery is expected to be completed within 1 month of the intervention as this would limit our ability to evaluate the effectiveness of the cryoneurolysis procedure * Allergies to local anesthetics * Inability to communicate with investigators * Opioid use disorder * History of severe psychiatric or medical conditions which hinder effective communication * Living more than 1 hour away from the hospital where the study is taking place or unable to travel to the hospital for the interventions and follow up * Body mass Index (BMI) ≥40 * Any contraindications specific to percutaneous cryoneurolysis such as history of bleeding diathesis, any active infections at the procedural site, cold urticaria, cryofibrinogenemia, cryoglobulinemia, paroxysmal cold hemoglobinuria, or Raynaud's disease (see Ilfeld \& Finneran, 2020) * Use of therapeutic anticoagulation * Diagnosis of Non-Osteoarthritis as the cause for THA or TKA * Other chronic pain condition which patients may be taking opioids to control the pain (e.g. Fibromyalgia or Complex Regional Pain Syndrome) * Less than 50% reduction in pain with diagnostic blocks using 0.5% bupivacaine

Design outcomes

Primary

MeasureTime frameDescription
Oral Morphine Equivalent ConsumptionPre-intervention, 2-weeks, 4-weeks, 8-weeks, 6 months, and 1-year post-intervention; 2-weeks, 6-weeks, 12-weeks postoperativeDaily Oral Morphine Equivalent Consumption

Secondary

MeasureTime frameDescription
NRS Pain ScorePre-intervention, 2-weeks, 4-weeks, 8-weeks, 6 months, and 1-year post-intervention; 2-weeks, 6-weeks, 12-weeks postoperativeNumerical Rating Scale Pain Score
EQ-5D ScorePre-intervention, 2-weeks, 4-weeks, 8-weeks, 6 months, and 1-year post-intervention; 2-weeks, 6-weeks, 12-weeks postoperativeEuroQol 5-Dimension Score
WOMAC ScorePre-intervention, 2-weeks, 4-weeks, 8-weeks, 6 months, and 1-year post-intervention; 2-weeks, 6-weeks, 12-weeks postoperativeWestern Ontario and McMaster Universities Osteoarthritis Index Score

Contacts

CONTACTRyan Endersby, MD
ryan.endersby@ahs.ca403-956-3827
PRINCIPAL_INVESTIGATORRyan Endersby, MD

University of Calgary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026